Role of MNK kinase pathway in regulating tumor immune microenvironment in pancreatic cancer
MNK激酶通路在胰腺癌肿瘤免疫微环境调节中的作用
基本信息
- 批准号:10357033
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:3&apos Untranslated RegionsAntitumor ResponseBindingCD8-Positive T-LymphocytesCTLA4 geneCXCL10 geneCXCL9 geneCellular ImmunityCellular immunotherapyCharacteristicsChemotactic FactorsClinicalClinical ResearchCombined Modality TherapyDevelopmentElementsEnzymesEukaryotic Initiation FactorsGenesGenetic TranslationGoalsHealthHumanImmune responseImmunologicsImmunosuppressionImmunotherapyInfiltrationLeadMalignant neoplasm of pancreasMediatingMissionOutcomePancreatic Ductal AdenocarcinomaPathway interactionsPatientsPhosphorylationPhosphotransferasesProteinsReactionRegimenRegulationReportingResearchRoleSliceSolid NeoplasmT-LymphocyteTestingTransgenic MiceTransgenic OrganismsTumor-associated macrophagesTumor-infiltrating immune cellsUnited States Department of Veterans AffairsVeteransanti-PD1 antibodiesarginasebasecancer cellcell typechemokinecytokineeffector T cellefficacy evaluationexhaustionexpectationimprovedimproved outcomein vivoinhibitorinnovationinsightinterestmacrophagemouse modelnovelnovel therapeutic interventionpancreatic cancer patientspancreatic ductal adenocarcinoma cellpancreatic ductal adenocarcinoma modelpancreatic neoplasmprogrammed cell death ligand 1programmed cell death protein 1protein expressionresponsetargeted treatmenttherapy resistanttraffickingtumortumor growthtumor-immune system interactions
项目摘要
Novel agents that can overcome the immunological barrier to CD8+ T cell infiltration and effector function have
the potential to improve clinical outcomes for pancreatic ductal adenocarcinoma (PDAC) patients. We have found
that targeting MNK kinases, which regulate mRNA translation, increases CD8+ T cell infiltration and expression
of T cell chemo-attractants. However, MNK inhibitors induce tumor-associated macrophages (TAMs) to express
the immunosuppressive protein Arginase-1, suggesting that MNK inhibitors polarize TAMs to cause CD8+ T cell
exhaustion. The main objective in this application is to identify mechanisms by which the MNK kinase pathway
regulates tumor infiltration by CD8+ T cells and modulates their effector function. The central hypothesis is that
targeting the MNK kinase pathway can overcome the immunological barriers to CD8+ T cell infiltration. A second
hypothesis is that MNK inhibitors demonstrate synergistic anti-tumor responses with therapies that overcome
CD8+ T cell exhaustion. Two specific aims are proposed: 1) Determine the mechanism by which the MNK kinase
pathway in cancer cells limits CD8+ T cell infiltration in PDAC tumors. 2) Determine the role of the MNK pathway
in TAMs and its regulation of the effector function of infiltrating CD8+ T cells in PDAC tumors. Under the first
aim, the mechanisms by which targeting the MNK pathway in PDAC cells increases T cell chemo-attractants will
be evaluated, focusing on the role of the downstream MNK target hnRNPA1. The effects of targeting hnRNPA1
in cancer cells on CD8+ T cell infiltration will also be assessed in the syngeneic orthotopic mouse model. In
additional studies, the effects of the combination therapy with a MNK inhibitor and an anti-PD-1 antibody on
CD8+ T cell infiltration and activation will be evaluated in the KPC transgenic mouse model of PDAC. For the
second aim, the contribution of MNK kinases and the MNK effector hnRNPA1 in macrophages to their
polarization and modulation of the CD8+ T cell effector function will be evaluated. The effects of combining MNK
and Arginase-1 inhibitors in ex vivo slice cultures of human PDAC tumors will also be assessed. In additional
studies, the efficacy of the triple regimen of a MNK inhibitor, an anti-PD-1 antibody, and an Arginase-1 inhibitor
will be evaluated in the KPC transgenic and the syngeneic orthotopic mouse models. There are several
innovative elements in this proposal, including novel concepts on the role of the MNK kinase pathway in
regulating CD8+ T cell infiltration and effector function, unique experimental approaches, and novel therapeutic
approaches to enhance immunotherapy responses in PDAC patients. This proposed research is significant
because it will have important clinical-translational implications and should result in the development of
mechanism-based novel combination therapies for PDAC patients.
可以克服CD8+ T细胞浸润和效应功能的免疫障碍的新型药物具有
改善胰腺导管腺癌(PDAC)患者临床结局的潜力。我们找到了
调节mRNA翻译的靶向MNK激酶会增加CD8+ T细胞浸润和表达
T细胞化学吸引力。但是,MNK抑制剂诱导肿瘤相关巨噬细胞(TAM)表达
免疫抑制蛋白精氨酸酶-1,表明MNK抑制剂极化TAM引起CD8+ T细胞
精疲力尽。该应用程序的主要目的是确定MNK激酶途径的机制
调节CD8+ T细胞的肿瘤浸润并调节其效应子功能。中心假设是
靶向MNK激酶途径可以克服CD8+ T细胞浸润的免疫障碍。第二
假设MNK抑制剂证明了与克服的疗法的协同抗肿瘤反应
CD8+ T细胞耗尽。提出了两个具体目标:1)确定MNK激酶的机制
癌细胞中的途径限制了PDAC肿瘤中的CD8+ T细胞浸润。 2)确定MNK途径的作用
在TAM中,其调节PDAC肿瘤中浸润CD8+ T细胞的效应子功能。在第一个
目的,针对PDAC细胞中MNK途径的机制会增加T细胞化学吸引者
进行评估,重点是下游MNK靶标HNRNPA1的作用。靶向HNRNPA1的影响
在CD8+ T细胞浸润的癌细胞中,还将在同步原位小鼠模型中评估。在
其他研究,组合疗法与MNK抑制剂和抗PD-1抗体的影响对
CD8+ T细胞浸润和激活将在PDAC的KPC转基因小鼠模型中评估。为了
第二个目的是巨噬细胞中MNK激酶和MNK效应子HNRNPA1的贡献
将评估CD8+ T细胞效应函数的极化和调节。组合MNK的效果
还将评估人体PDAC肿瘤的离体切片培养物中的精氨酸酶-1抑制剂。附加
研究,MNK抑制剂三重方案的功效,抗PD-1抗体和精氨酸酶-1抑制剂的疗效
将在KPC转基因和合成原位小鼠模型中进行评估。有几个
该提案中的创新元素,包括有关MNK激酶途径在
调节CD8+ T细胞浸润和效应子功能,独特的实验方法和新型治疗
增强PDAC患者免疫疗法反应的方法。这项拟议的研究很重要
因为它将具有重要的临床翻译意义,并应导致发展
基于机理的PDAC患者的新型组合疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hidayatullah G. Munshi其他文献
MT1-MMP cooperates with kras to generate intraductal papillary mucinous neoplasms with pronounced fibrosis
- DOI:
10.1016/j.jamcollsurg.2010.06.323 - 发表时间:
2010-09-01 - 期刊:
- 影响因子:
- 作者:
Seth B. Krantz;Surabhi Dangi-Garimella;Mario A. Shields;Paul J. Grippo;David J. Bentrem;Hidayatullah G. Munshi - 通讯作者:
Hidayatullah G. Munshi
Hidayatullah G. Munshi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hidayatullah G. Munshi', 18)}}的其他基金
Ex vivo slice cultures of mouse pancreatic tumors to test novel regimens
小鼠胰腺肿瘤的离体切片培养物测试新疗法
- 批准号:
10361971 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Co-targeting BET Bromodomain Proteins and MNK Kinases in Pancreatic Cancer
胰腺癌中 BET 溴结构域蛋白和 MNK 激酶的共同靶向
- 批准号:
10338560 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Role of MNK kinase pathway in regulating tumor immune microenvironment in pancreatic cancer
MNK激酶通路在胰腺癌肿瘤免疫微环境调节中的作用
- 批准号:
10653681 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Co-targeting BET Bromodomain Proteins and MNK Kinases in Pancreatic Cancer
胰腺癌中 BET 溴结构域蛋白和 MNK 激酶的共同靶向
- 批准号:
10533366 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Ex vivo slice cultures of mouse pancreatic tumors to test novel regimens
小鼠胰腺肿瘤的离体切片培养物测试新疗法
- 批准号:
10653683 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Rapid evaluation of immunotherapy regimens in ex vivo human pancreatic tumor slice cultures.
快速评估离体人胰腺肿瘤切片培养物中的免疫治疗方案。
- 批准号:
10312775 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Diversity Supplement to R01 Parent Grant CA186885
R01 家长补助金 CA186885 的多样性补充
- 批准号:
9251089 - 财政年份:2014
- 资助金额:
-- - 项目类别:
相似海外基金
Role of MNK kinase pathway in regulating tumor immune microenvironment in pancreatic cancer
MNK激酶通路在胰腺癌肿瘤免疫微环境调节中的作用
- 批准号:
10653681 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Leveraging Zika virus and the immune system to treat glioblastoma
利用寨卡病毒和免疫系统治疗胶质母细胞瘤
- 批准号:
10528449 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Vesicular Stomatitis Virus (VSV) Replication in Malignant Cells
水泡性口炎病毒 (VSV) 在恶性细胞中的复制
- 批准号:
9752480 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Mechanisms of AKT-dependent sensitivity to rapamycin
AKT 依赖性雷帕霉素敏感性机制
- 批准号:
7409068 - 财政年份:2005
- 资助金额:
-- - 项目类别:
Mechanisms of AKT-dependent sensitivity to rapamycin
AKT 依赖性雷帕霉素敏感性机制
- 批准号:
7230526 - 财政年份:2005
- 资助金额:
-- - 项目类别: